Affiliation:
1. From the Institute for Translational Medicine and Therapeutics (R.E.M., J.S.M., D.J.R.), University of Pennsylvania School of Medicine, Philadelphia; Department of Medicine (M.N., S.H.), David Geffen School of Medicine at UCLA, Los Angeles, Calif; and Division of Gastroenterology and Nutrition (F.Z., G.H.R.), Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pa.
Abstract
To test the hypothesis that apolipoprotein A-I (apoA-I) functions specifically to inhibit atherosclerosis independent of the level of high-density lipoprotein cholesterol (HDL-C) by promoting both reverse cholesterol transport and HDL antiinflammatory function in vivo, we established a murine atherosclerosis model of apoA-I deficiency in which the level of HDL-C is well maintained. ApoA-I
−/−
mice were crossed with atherosclerosis susceptible low-density lipoprotein receptor
−/−
/apobec
−/−
(LA) mice to generate LA mice with apoA-I
+/+
, apoA-I
+/−
, and apoA-I
−/−
genotypes. There were no major differences in the amounts of non–HDL-C and HDL-C in the plasma between different apoA-I genotypes. A significant inverse relationship was observed, however, between apoA-I gene dose and atherosclerosis in both female and male mice. Compared with LA-apoA-I
+/+
mice, serum from LA-apoA-I
−/−
mice had a significantly reduced capacity to function as an acceptor of ABCA1- and SR-BI-mediated cellular cholesterol efflux, and also had markedly reduced lecithin cholesterol acyltransferase activity. In addition, LA-apoA-I
−/−
mice had significantly reduced macrophage-derived cholesterol esterification and reverse cholesterol transport in vivo. There was significantly reduced plasma paraoxonase (PON-1) activity, impaired HDL vascular antiinflammatory function, and increased basal levels of monocyte chemotactic protein-1 in the plasma of LA-apoA-I
−/−
mice compared with LA-apoA-I
+/+
mice. In LA-apoA-I
−/−
mice, there was also greater induction of some, but not all, inflammatory cytokines and chemokines in response to intraperitoneal injection of lipopolysaccharide than in LA-apoA-I
+/+
mice. We conclude that apoA-I inhibits atherosclerosis by promoting both macrophage reverse cholesterol transport and HDL antiinflammatory function, and that these anti-atherogenic functions of apoA-I are largely independent of the plasma level of HDL-C in this mouse model.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine,Physiology
Cited by
159 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献